Myasthenia Gravis clinical trials at UC Cancer
6 research studies open to eligible people
A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness.
open to eligible people ages 18 years and up
This is a Long-Term, Single-Arm, Open-Label, Multicenter Phase 3 follow-on trial of the ARGX-113-1704 study to evaluate the safety and tolerability of ARGX-113 in patients with gMG.
at UCLA
A Study of RVT-1401 in Myasthenia Gravis (MG) Patients
open to eligible people ages 18 years and up
The purpose of the current study is to assess safety/tolerability and key pharmacodynamic (PD) effects that are considered to be associated with clinical benefit (reduction of total IgG and anti-AChR-IgG) in Myasthenia Gravis patients following treatment with RVT-1401 (also known as IMVT-1401) compared to placebo.
at UC Irvine
Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)
open to eligible people ages 18 years and up
This is a Phase Ib/IIa study to evaluate the safety and preliminary efficacy of Descartes-08 CAR T-cells in patients with Generalized Myasthenia Gravis
at UC Irvine
Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis
open to eligible people ages 18 years and up
The RAISE-XT study is an open-label extension study to evaluate the long-term efficacy, safety, and tolerability of zilucoplan in subjects with gMG who have previously participated in a qualifying Ra Pharmaceuticals sponsored zilucoplan study.
at UC Irvine
Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis
open to eligible people ages 18 years and up
The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab for the treatment of participants with generalized myasthenia gravis (gMG).
at UC Irvine UCLA
Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis
open to eligible people ages 18-75
The RAISE study is a multicenter, randomized, double-blind, placebo controlled study to confirm the efficacy, safety, and tolerability of zilucoplan in subjects with generalized Myasthenia Gravis. Subjects will be randomized in a 1:1 ratio to receive daily SC doses of 0.3 mg/kg zilucoplan or placebo for 12 weeks.
at UC Irvine
Last updated: